Outputs (7)

The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer (2020)
Journal Article
Elsharawy, K. A., Mohammed, O. J., Aleskandarany, M. A., Hyder, A., El-Gammal, H. L., -Dobara, A., Green, A. R., Dalton, L. W., & Rakha, E. A. (2020). The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer. British Journal of Cancer, 123, 1543–1552. https://doi.org/10.1038/s41416-020-01045-7

Background

Hypertrophy of the nucleolus is a distinctive cytological feature of malignant cells and corresponds to aggressive behaviour. This study aimed to identify the key gene associated with nucleolar prominence (NP) in breast cancer (BC) and... Read More about The nucleolar related protein Dyskerin pseudouridine 1 synthase 1 (DKC1) predicts poor prognosis in breast cancer.

Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets (2020)
Journal Article
Kurozumi, S., Alsaleem, M., Monteiro, C. J., Bhardwaj, K., Joosten, S. E., Fujii, T., Shirabe, K., Green, A. R., Ellis, I. O., Rakha, E. A., Mongan, N. P., Heery, D. M., Zwart, W., Oesterreich, S., & Johnston, S. J. (2020). Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets. Breast Cancer Research, 22, Article 85. https://doi.org/10.1186/s13058-020-01324-4

© 2020 The Author(s). Background: Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tractable... Read More about Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets.

PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer (2020)
Journal Article
Alfarsi, L. H., El Ansari, R., Craze, M. L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer. BMC Cancer, 20(1), Article 425. https://doi.org/10.1186/s12885-020-06939-6

Background
PPFIA1 is an important regulator of cell migration and invasion, regulating focal adhesion signalling and disassembly. PPFIA1 is frequently amplified in breast cancer, and recent functional studies indicate that PPFIA1 is an important pro... Read More about PPFIA1 expression associates with poor response to endocrine treatment in luminal breast cancer.

The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer (2020)
Journal Article
Ansari, R., Craze, M. L., Alfarsi, L., Masisi, B. K., Ellis, I. O., Rakha, E. A., & Green, A. R. (2020). The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer. Breast Cancer Research and Treatment, 181(1), 1-12. https://doi.org/10.1007/s10549-020-05586-6

Purpose: Breast cancer (BC) is a heterogeneous disease consisting of various subtypes, with
different prognostic and therapeutic outcomes. The amino acid transporter, SLC7A8, is over expressed in estrogen receptor positive BC. However the consequenc... Read More about The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.

PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression (2020)
Journal Article
Huang, P., Gagliano, T., Shah, K., Gargani, S., Lao, L., Alsaleem, M., Chen, J., Ntafis, V., Ditsiou, A., Vella, V., Yadav, K., Bienkowska, K., Bresciani, G., Kang, K., Li, L., Carter, P., Benstead-Hum, G., O'hanlon, T., Dean, M., Pearl, F. M. G., …Giamas, G. (2020). PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression. Journal of Clinical Investigation, 130(6), 3188-3204. https://doi.org/10.1172/jci128313

As there is growing evidence for the tumor microenvironment’s (TME) role in tumorigenesis, we investigated the role of fibroblast-expressed kinases in triple negative breast cancer (TNBC). Using a high-throughput kinome screen combined with 3D invasi... Read More about PIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression.

Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer (2020)
Journal Article
Alfarsi, L. H., El-Ansari, R., Craze, M. L., Masisi, B. K., Mohammed, O. J., Rakha, E. A., Ellis, I. O., & Green, A. R. (2020). Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer. International Journal of Molecular Sciences, 21(4), Article 1407. https://doi.org/10.3390/ijms21041407

The majority of breast cancers are oestrogen receptor positive (ER+) and are subject to endocrine therapy however, an unpredictable subgroup of patients will develop resistance to endocrine therapy. SLC7A5/SLC3A2 complex is a major route for the tran... Read More about Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.

The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer (2020)
Journal Article
Vangangelt, K. M., Green, A. R., Heemskerk, I. (. F., Cohen, D., Van Pelt, G. W., Sobral-Leite, M., Schmidt, M. K., Putter, H., Rakha, E. A., Tollenaar, R. A., & Mesker, W. E. (2020). The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer. International Journal of Cancer, 146(8), 2296-2304. https://doi.org/10.1002/ijc.32857

The tumor-stroma ratio (TSR) was evaluated as a promising parameter for breast cancer prognostication in clinically relevant subgroups of patients. The TSR was assessed on hematoxylin and eosin stained tissue slides of 1794 breast cancer patients fro... Read More about The prognostic value of the tumor–stroma ratio is most discriminative in patients with grade III or triple‐negative breast cancer.